This is not Li Miaomiao's first visit to England. He had been to Cambridge and Oxford during his high school vacation.

The feeling of coming to England this time is different from the last time. This time I came with a goal. Kechuang Biotech wants to acquire an AI chip company in England and build an AI chip R&D center in England based on it.

Seind is only the first target of Kechuang Biotech, and there are several other companies as alternatives.

This was also the first time he went abroad after the global epidemic spread. Li Miaomiao took a deep breath after getting off the plane. She was almost starving of oxygen while wearing an N95 on the plane.

"Everyone, go through the prepared materials again when you arrive at the hotel today, so there won't be any mistakes tomorrow."

Li Miaomiao specifically asked her to be responsible for this trip to England because she wanted to stop by the Lion City and visit Zheng Li on her way back.

"We are a biopharmaceutical company in China and hope to acquire your company. We will not interfere with the normal operations of the company in the first three years after acquiring the company."

The reason why Gouchang is more popular than Ahli in the investment community is that Gouchang rarely interferes in the operations of its investment companies, while Ahli likes to participate in the operations of investment companies and replaces the executives of its investment companies with Ahli.

of employees.

In the investment circle, Ali is much more domineering than Goose Factory.

"We will only give you advice on AI chips and algorithms."

"The benefits of employees and executives will remain unchanged."

"This is the information of Science and Technology Biotech, you can take a look."

As a global leader in the field of brain-computer connection, Kechuang Biotechnology is still well-known.

Although the specific company name may not be named, foreigners can instantly understand it when it comes to the Chinese company that specializes in brain-computer connection with mobile phones and endorphins.

Endorphins are as well-known in the field of biomedicine as brain-computer connection.

After the simultaneous interpreter translated Li Miaomiao's words, Seind's chairman nodded: "Okay, let me take a look first."

The conference room was quiet, except for the rustling of pages.

"I do not deny that Kechuang Biotech is an outstanding company and has made unique contributions in its own field."

"But we are very curious, why does Kechuang Biotech want to acquire seind? From the company's information, we can see that there is no overlap in our fields."

"Seind mainly makes AI algorithms and AI chips related to autonomous driving, while Kechuang Biotech seems to be engaged in brain-computer connection in addition to biomedicine."

"When your company acquires us, I feel there is very little overlap and complementarity."

"So why should we accept your acquisition?"

Regarding the other party's embarrassment, Li Miaomiao was very calm:

"Seind has not accepted new investment since it started Series B investment in 2019. Moreover, Seind's valuation of Series B investment in 19 was 100 million yuan, but the actual funds raised were only 24 million yuan."

"Affected by the epidemic in the past two years, the price of chip foundry has been rising year by year, and labor costs are also rising. I wonder how long Seind can last without investment?"

"As an AI chip company in England, Graphcore received a large amount of funding last year, and DeepMind has been backed by Google since 2014."

"How can Seind survive? The revenue from the cooperation with Mazda is limited and it should not be able to support the company's further development."

England is an important place for AI research. Over the years, multinational giants have continued to invest in English AI companies, but there are very few Chinese companies.

HP announced the acquisition of Autonomy. Amazon acquired True Knowledge; in 2014, Google acquired deepmind, Dark Blue Labs, Vision Factory, Apple acquired VocalIQ, and Microsoft acquired SwiftKey, Tony.

The ones behind are all companies in the field of artificial intelligence in England, not all AI chips.

"We have sufficient funds, and other investment institutions have expressed their willingness to participate in Seind's Series C investment."

"We will soon promote Seind's Series C fundraising, and we very much welcome the participation of giants like Kechuang Biotech."

They welcome investment, but don't want to be acquired.

Li Miaomiao is very suspicious. No one has invested in you in the past two years. As soon as we said we wanted to acquire it, someone came to invest?

On second thought, Cheng Gang told him when she was on the way that Goldman Sachs and IDG also wanted to participate in seind's investment.

"Do IDG and Goldman Sachs want to invest in you?"

The other party nodded: "Now that you know, I have nothing to hide."

"IDG and Goldman Sachs have signed share transfer memorandums with our shareholders respectively, and the two investment institutions have stated that they will help us start the C round of fundraising as soon as possible."

"IDG and Goldman Sachs will lead the investment."

Li Miaomiao thought to herself that these investment institutions were really shameless. They knew that Kechuang Biotech was going to acquire seind ​​and they acted more decisively than they did.

Kechuang Biotech still has many shortcomings in this regard. If it were a goose factory, it would have completed this matter long ago without anyone noticing.

The first meeting ended in a hurry, and Li Miaomiao felt that she needed to review the specific circumstances of the matter.

Then figure out the intentions of IDG and Goldman Sachs.

Currently, the only shareholders of Seind are Goldman Sachs, IDG, Goose Factory, Cambridge University Investment Fund and its founders.

The shareholding structure is simple, but there is no fuel-saving light in it.

...

Kechuang Biotechnology issued an announcement at 0:00 a.m. on New Year's Day. The content of the announcement was to the effect:

"Kechuang Biotech has completed the research and development of brain-computer connection for all English-speaking people in mobile phones. Patents are being registered globally, and patent licensing negotiations have begun simultaneously with major mobile phone manufacturers."

It also explains that the licensing price of English-language brain-computer connection patents needs to be adjusted. It will not be like the Chinese-language patent licensing price of 200 yuan per mobile phone.

As soon as the news came out, the top ten science and technology biotech stocks were quickly pushed to the first place:

"Good landing, let's dive high!"

There are many such comments. Not only does it make sense to dive at a high level, but people in the stock market have a mentality that if the company is doing well and I don’t have a position, then I am mindlessly bearish.

"The current price of Kechuang Biotechnology, which is only over 2,000 yuan, is not high. In the short term, it is expected to reach 3,000 yuan."

Currently, Kechuang Biotechnology and Moutai are the only two companies in the A-share market whose stock prices exceed 2,000 yuan.

Liquor companies have been rising, so much so that stock investors joked that China’s technology stocks are Maotai Technology and Luzhou Technology.

Most investors are still happy to see technology stocks represent China's stock exchange market rather than wine companies.

"The patent licensing of English-language brain-computer connection to mobile phones will release at least RMB 6 billion in profits for Kechuang Biotech in 2022. This is based on the current patent licensing price.

If the price is renegotiated, the net profit will still rise.

Profit is not the most important thing, but what is more critical is that Kechuang Biotech was the first to issue an announcement, showing that it is still the strongest company in the field of brain-computer connection.

Kechuang Biotechnology's revenue in the field of brain-computer connection is the combined revenue of all other companies in the field of brain-computer connection.
Chapter completed!